Daphne Chan

2.4k total citations · 1 hit paper
47 papers, 1.6k citations indexed

About

Daphne Chan is a scholar working on Immunology, Pediatrics, Perinatology and Child Health and Genetics. According to data from OpenAlex, Daphne Chan has authored 47 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 19 papers in Pediatrics, Perinatology and Child Health and 15 papers in Genetics. Recurrent topics in Daphne Chan's work include Psoriasis: Treatment and Pathogenesis (19 papers), Inflammatory Bowel Disease (15 papers) and Prenatal Substance Exposure Effects (10 papers). Daphne Chan is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (19 papers), Inflammatory Bowel Disease (15 papers) and Prenatal Substance Exposure Effects (10 papers). Daphne Chan collaborates with scholars based in Canada, United States and Germany. Daphne Chan's co-authors include Gideon Koren, Philippe Szapary, Julia Klein, Yasmine Wasfi, Kim Papp, Mark Lebwohl, Kenneth B. Gordon, Kristian Reich, Bruce Strober and C.E.M. Griffiths and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Daphne Chan

45 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

2022 132 citations William J. Sandborn, Geert D’Haens et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daphne Chan Canada	20	856	497	371	348	331	47	1.6k
Yasmine Wasfi United States	19	2.8k 3.2×	225 0.5×	187 0.5×	1.7k 5.0×	263 0.8×	40	3.2k
Zenas Z N Yiu United Kingdom	21	1.2k 1.5×	79 0.2×	195 0.5×	898 2.6×	95 0.3×	72	1.8k
Jeffrey Crowley United States	24	1.5k 1.7×	57 0.1×	116 0.3×	866 2.5×	244 0.7×	64	1.9k
Valderílio Feijó Azevedo Brazil	22	921 1.1×	68 0.1×	135 0.4×	132 0.4×	165 0.5×	116	1.8k
Micol Del Giglio Italy	15	875 1.0×	56 0.1×	77 0.2×	460 1.3×	137 0.4×	28	1.3k
Thomas Salko United States	5	1.3k 1.5×	85 0.2×	51 0.1×	720 2.1×	108 0.3×	5	1.6k
P. de la Cueva Spain	22	904 1.1×	46 0.1×	141 0.4×	554 1.6×	84 0.3×	107	1.2k
Sarah Rogers United States	12	323 0.4×	116 0.2×	54 0.1×	299 0.9×	111 0.3×	20	933
Lars Erik Bryld Denmark	18	764 0.9×	32 0.1×	168 0.5×	733 2.1×	101 0.3×	34	1.3k
Michael Reusch Germany	21	280 0.3×	67 0.1×	49 0.1×	478 1.4×	234 0.7×	79	1.6k

Countries citing papers authored by Daphne Chan

Since Specialization

Citations

This map shows the geographic impact of Daphne Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daphne Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daphne Chan more than expected).

Fields of papers citing papers by Daphne Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daphne Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daphne Chan. The network helps show where Daphne Chan may publish in the future.

Co-authorship network of co-authors of Daphne Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Daphne Chan. A scholar is included among the top collaborators of Daphne Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daphne Chan. Daphne Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gold, Linda Stein, Alice B. Gottlieb, April W. Armstrong, et al.. (2025). SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. British Journal of Dermatology. 194(1). 25–36.

Alexis, Andrew, Amy McMichael, Neelam A. Vashi, et al.. (2024). Improving Diversity in a Novel Psoriasis Study. JAMA Dermatology. 161(3). 256–256. 5 indexed citations

Blauvelt, Andrew, Diamant Thaçi, Kim Papp, et al.. (2023). Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. British Journal of Dermatology. 189(1). 132–134. 8 indexed citations

Strober, Bruce, Laura C. Coates, Mark Lebwohl, et al.. (2023). Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug Safety. 47(1). 39–57. 31 indexed citations

Lebwohl, Mark, Joseph F. Merola, Megan Miller, et al.. (2023). Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure. British Journal of Dermatology. 189(1). 42–52. 21 indexed citations

Blauvelt, Andrew, Mark Lebwohl, Richard G. Langley, et al.. (2023). Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology. 89(2). 274–282. 12 indexed citations

Merola, Joseph F., et al.. (2023). A clinical review of structural damage in psoriatic arthritis for dermatologists: From pathogenesis to ongoing controversies. Journal of the American Academy of Dermatology. 90(2). 349–357. 6 indexed citations

Sandborn, William J., Geert D’Haens, Walter Reinisch, et al.. (2022). Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 162(6). 1650–1664.e8. 132 indexed citations breakdown →

Li, Katherine, Joshua R. Friedman, Daphne Chan, et al.. (2019). Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease. Gastroenterology. 157(4). 1019–1031.e7. 48 indexed citations

10.

Rutgeerts, Paul, Christopher Gasink, Daphne Chan, et al.. (2018). Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease. Gastroenterology. 155(4). 1045–1058. 115 indexed citations

11.

Xu, Yan, Omoniyi J. Adedokun, Daphne Chan, et al.. (2018). Population Pharmacokinetics and Exposure‐Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. The Journal of Clinical Pharmacology. 59(4). 590–604. 31 indexed citations

12.

Papp, Kim, C.E.M. Griffiths, Kenneth B. Gordon, et al.. (2013). Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. British Journal of Dermatology. 168(4). 844–854. 318 indexed citations

13.

Kimball, Alexa B., Kim Papp, Yasmine Wasfi, et al.. (2012). Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study. Journal of the European Academy of Dermatology and Venereology. 27(12). 1535–1545. 162 indexed citations

14.

Poulin, Yves, et al.. (2010). A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. International Journal of Dermatology. 49(12). 1368–1375. 36 indexed citations

15.

Brien, James F., Daphne Chan, Courtney R. Green, et al.. (2006). Chronic Prenatal Ethanol Exposure and Increased Concentration of Fatty Acid Ethyl Esters in Meconium of Term Fetal Guinea Pig. Therapeutic Drug Monitoring. 28(3). 345–350. 28 indexed citations

16.

Chan, Daphne, Daniela Caprara, Phillip Blanchette, Julia Klein, & Gideon Koren. (2004). Recent developments in meconium and hair testing methods for the confirmation of gestational exposures to alcohol and tobacco smoke. Clinical Biochemistry. 37(6). 429–438. 66 indexed citations

17.

Chan, Daphne, Brenda Knie, Rada Boskovic, & Gideon Koren. (2004). Placental Handling of Fatty Acid Ethyl Esters: Perfusion and Subcellular Studies. Journal of Pharmacology and Experimental Therapeutics. 310(1). 75–82. 40 indexed citations

18.

Koren, Gideon, et al.. (2004). Is it all right to drink a little during pregnancy?. PubMed. 50. 1643–4. 2 indexed citations

19.

Chan, Daphne, Benjamin Bar‐Oz, Julia Klein, et al.. (2003). Population Baseline of Meconium Fatty Acid Ethyl Esters Among Infants of Nondrinking Women in Jerusalem and Toronto. Therapeutic Drug Monitoring. 25(3). 271–278. 106 indexed citations

20.

Koren, Gideon, et al.. (2002). Estimation of Fetal Exposure to Drugs of Abuse, Environmental Tobacco Smoke, and Ethanol. Therapeutic Drug Monitoring. 24(1). 23–25. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact